Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
GREENFIELD, Ind. -On Tuesday, Elanco Animal Health Incorporated (NYSE:ELAN) reported fourth quarter 2024 financial results that fell short of analyst expectations, while providing guidance for 2025 below consensus estimates.
The company’s stock was down -0.54% in pre-market trading following the earnings release.
The animal health company posted adjusted earnings per share of $0.14 for Q4, missing the analyst estimate of $0.15. Revenue came in at $1.02 billion, slightly above the $1.01 billion consensus forecast.
For the full year 2025, Elanco projects earnings per share of $0.80 to $0.86, below the $0.90 analysts were expecting. The company forecasts 2025 revenue between $4.445 billion and $4.51 billion, also under the $4.534 billion consensus estimate.
Elanco’s Q4 revenue decreased 1% year-over-year on a reported basis but increased 4% on an organic constant currency basis. Pet Health revenue rose 6% to $439 million, while Farm Animal revenue fell 7% to $570 million.
"Elanco delivered a strong finish to 2024, achieving our sixth consecutive quarter of organic constant currency revenue growth - with the fourth quarter up 4% - and building momentum as we head into 2025," said Jeff Simmons, President and CEO of Elanco Animal Health.
Elanco expects accelerating organic constant currency revenue growth to mid-single digits in 2025.
Elanco ended 2024 with a net leverage ratio of 4.3x adjusted EBITDA, unchanged from the previous quarter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.